The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | MRD in CLL: in which settings is its use most important?
Jennifer Woyach
• 7 Dec 2019
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the use of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL). Dr Woyach highlights how the treatment used impacts the prognostic nature of MRD status. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
